Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant tumor necrosis factor-thymosin alpha 1 fusion protein
- Development stage
- Unknown
- Lead developer
- Refnot-Pharm
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Recombinant tumor necrosis factor-thymosin alpha 1 fusion protein is a recombinant fusion protein composed of the human pro-inflammatory cytokine tumor necrosis factor alpha (TNFalpha) and the immunostimulatory peptide thymosin alpha 1 (Ta1). This fusion protein possesses potential immunomodulatory and antineoplastic activities. The TNFalpha moiety is designed to induce an immune response, leading to apoptosis, tumor cell death, tumor vascular destruction, and tumor necrosis. Concurrently, the Ta1 moiety interacts with various Toll-like receptors (TLRs), which promotes the production of various cytokines and enhances both innate and adaptive immune responses against tumor cells. It is considered a TNFR modulator and has shown efficacy in neoplastic diseases.
- Other names
- recombinant TNFalpha-Ta1 fusion proteinRecombinant alpha-tumor necrosis factor-thymosin-alpha-1
02
Targets
TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)TLR2 (Toll-like Receptor 2)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on recombinant tumor necrosis factor-thymosin alpha 1 fusion protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant tumor necrosis factor-thymosin alpha 1 fusion protein.